Table 1 A comparison between unilateral and bilateral PCN for bilateral obstructed kidneys with malignant ureteral obstruction

Age (year)

62.8 ± 13.7 (24–82; 58.9–66.7)

56.5 ± 15.3 (23–86; 52.3–60.8)

Gender

 Men

37 (74%)

36 (69.2%)

 Women

13 (26%)

16 (30.8%)

BMI (kg/m²)

24.4 ± 4.9 (16.1–36.9; 23–25.8)

24.7 ± 4.8 (17.3–35.9; 23.4–26.1)

Comorbidity

 Yes

17 (34%)

12 (23.1%)

 None

33 (66%)

40 (76.9%)

Smoking

 Yes

10 (20%)

13 (25%)

 No

40 (80%)

39 (75%)

Previous surgery

 Yes

5 (10%)

8 (15.4%)

 None

45 (90%)

44 (84.6%)

Pain

 Bilateral

17 (63%)

17 (60.7%)

 Left

4 (14.8%)

6 (21.4%)

 Right

6 (22.2%)

5 (17.9%)

Temperature

37.2 ± 0.5 (36.0–38.8; 37.0–37.3)

37.3 ± 0.4 (36.5–38.6; 37.1–37.4)

UOP status at presentation

 Normal

38 (76%)

27 (51.9%)

 Low

12 (24%)

25 (48.1%)

Tenderness

 Bilateral

4 (57.1%)

6 (60%)

 Unilateral

3 (42.9%)

4 (40%)

Pre dialysis sessions

 Once

7 (77.78%)

5 (41.67%)

 More than one

2 (22.22%)

7 (58.33%)

Uremic symptoms

 Present

7 (14%)

11 (21.2%)

 Absent

43 (86%)

41 (78.8%)

Mean parenchymal thickness (mm)

13 ± 2 (8.5–16; 12.4–13.6)

12.6 ± 2 (8–16;12–13.1)

Type of malignancy relative to urinary tract

 Urinary

34 (68%)

31 (59.6%)

 Extraurinary

16 (32%)

21 (40.4%)

Pathological type of malignancy

 Bladder cancer

27 (54%)

28 (53.8%)

 Prostate cancer

7 (14%)

3 (5.8%)

 Colorectal cancer

9 (18%)

11 (21.2%)

 Cervical cancer

6 (12%)

8 (15.4%)

 Lymphoma

1 (2%)

2 (3.8%)

Random blood sugar

124.8 ± 56.9 (45–330; 108.6–140.9)

126.9 ± 53 (72–315; 112.1–141.6)

Blood PH

7.37 ± 0.07 (7.18–7.47; 7.35–7.39)

7.36 ± 0.07 (7.15–7.47; 7.34–7.38)

PCO₂ (mmHg)

25.1 ± 5.2 (15–36; 23.66–26.62)

24.1 ± 6.1 (14–36; 22.4–25.8)

Bicarbonate defect (mmol/L)

− 7.5 ± 5.4 {− 21 to 1; − 9.07–(− 5.99)}

− 9.13 ± 5.55 {− 21 to 1; − 10.67–(− 7.58)}

HCO₃ (mmol/L)

15.8 ± 3.9 (9–23; 14.7–17)

15.7 ± 4.3 (6.7–22.5; 14.4–16.9)

SCr at presentation (mg/dL)

5.8 ± 3.2 (2–17; 4.9–6.7)

6.8 ± 3.1 (2.2–14; 5.9–7.6)

Postoperative SCr measures (mg/dL)

 SCr at 1st day

4.7 ± 2.8 (1.3–14.8; 3.9–5.5)

5.8 ± 2.7 (1.5–12.3; 5.1–6.5)

 SCr at 3rd day

3.9 ± 2.7 (0.8–13; 3.1–4.6)

4.8 ± 2.5 (0.8–11; 4.1–5.5)

 SCr at 5th day

3 ± 2 (0.6–8.2; 2.5–3.6)

3.7 ± 2.2 (0.7–9.1; 3.1–4.3)

 SCr at 7th day

2.5 ± 1.6 (0.5–6.9; 2–3)

2.9 ± 2.1 (0.5–10.6; 2.3–3.5)

 SCr at 10th day

2.1 ± 1.3 (0.3–5.2; 1.8–2.5)

2.2 ± 1.4 (0.3–4.4; 1.9–2.6)

 SCr at 15th day

1.4 ± 0.7 (0.4–3.9; 1.2–1.6)

1.3 ± 0.7 (0.4–3.5; 1.1–1.5)

 SCr at 21st day

1.4 ± 0.6 (0.4–2.5; 1.2–1.6)

1.2 ± 0.5 (0.4–2.5; 1.1–1.3)

Time-to-nadir SCr (days)

12.6 ± 5.2 (3–21; 11.1–14)

12.7 ± 5.4 (3–21; 11.2–14.2)

SCr normalization Rate

 Yes

24 (48%)

34 (65.4%)

 No

26 (52%)

18 (34.6%)

Pus cells in urine after drainage/HPF

27.8 ± 28.2 (5–100; 19.8–35.8)

30.8 ± 29.9 (3–100; 22.4–39.1)

SCr-Trs (mg/dL/day)

SCr-Tr during 1st 3 days

0.7 ± 0.7 (− 1 to 3.2; 0.5–0.9)

0.7 ± 0.6 (− 0.3 to 3.3; 0.5–0.82)

Mode of SCr-Tr during 1st 3 days at 0.3 mg/dL/day value

Rapid (≥ 0.3 mg/dL/day)

32 (64%)

37 (71.2%)

Slow(< 0.3 mg/dL/day)

18 (36%)

15 (28.8%)

Mode of SCr-Tr during 1st 3 days at 0.5 mg/dL/day value

Rapid (≥ 0.5 mg/dL/day)

24 (48.0%)

28 (53.85%)

Slow(< 0.5 mg/dL/day)

26 (52.0%)

24 (46.15%)

Mode of SCr-Tr during 1st 3 days at 0.7 mg/dL/day value

Rapid (≥ 0.7 mg/dL/day)

18 (36.0%)

19 (36.54%)

Slow(< 0.7 mg/dL/day)

32 (64.0%)

33 (63.46%)

Mode of SCr-Tr during 1st 3 days at 1 mg/dL/day value

Rapid (≥ 1 mg/dL/day)

11 (22%)

11 (21.2%)

Slow(< 1 mg/dL/day)

39 (78%)

41 (78.8%)

SCr-Tr during 1st week

0.5 ± 0.4 (0.03–1.7; 0.4–0.6)

0.6 ± 0.4 (− 0.5 to 1.6; 0.4–0.7)

Mean SCr-Tr during time-to-nadir SCr (mg/dL/day)

0.4 ± 0.4 (0.03–2.1; 0.3–0.6)

0.6 ± 0.4 (0.1–2.3; 0.4–0.7)

Modes of SCr-Tr during time-to-nadir SCr at 0.1 mg/dL/day value

Rapid (≥ 0.1 mg/dL/day)

47 (94%)

52 (100%)

Slow (< 0.1 mg/dL/day)

3 (6%)

0 (0%)

Modes of SCr-Tr during time-to-nadir SCr at 0.3 mg/dL/day value

Rapid (≥ 0.3 mg/dL/day)

30 (60%)

34 (65.4%)

Slow (< 0.3 mg/dL/day)

20 (40%)

18 (34.6%)

Modes of SCr-Tr during time-to-nadir SCr at 0.5 mg/dL/day value

Rapid (≥ 0.5 mg/dL/day)

15 (30%)

23 (44.2%)

Slow (< 0.5 mg/dL/day)

35 (70%)

29 (55.8%)

SCr-Tr during 1st 3 days–SCr-Tr during 1st week (mg/dL/day)

0.2 ± 0.5 (− 1.3 to 1.7; 0.1–0.3)

0.1 ± 0.3 (− 0.4 to 1.7; 0.01–0.2)

SCr-Tr during 1st 3 days–SCr-Tr during time-to-nadir (mg/dL/day)

0.2 ± 0.5 (− 1.3 to 1.6; 0.1–0.4)

0.1 ± 0.3 (− 0.7 to 1.2; 0.0–0.2)